Market capitalization | $380.63m |
Enterprise Value | $407.64m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.98 |
P/S ratio (TTM) P/S ratio | 6.52 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 25.45% |
Revenue (TTM) Revenue | $58.36m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Aquestive Therapeutics, Inc. forecast:
8 Analysts have issued a Aquestive Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 58 58 |
25%
25%
|
|
Gross Profit | 40 40 |
59%
59%
|
|
EBITDA | -14 -14 |
48%
48%
|
EBIT (Operating Income) EBIT | -15 -15 |
46%
46%
|
Net Profit | -26 -26 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Head office | United States |
CEO | Daniel Barber |
Employees | 135 |
Founded | 2004 |
Website | www.aquestive.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.